Intraarterial delivery of virotherapy for glioblastoma

被引：18
作者：
Srinivasan, Visish M. [1 ]
Lang, Frederick F. [2 ]
Kan, Peter [3 ]
机构：
[1] Barrow Neurol Inst, Dept Neurosurg, Phoenix, AZ 85013 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA
[3] Univ Texas Med Branch, Dept Neurosurg, Galveston, TX 77555 USA
来源：
NEUROSURGICAL FOCUS | 2021年 / 50卷 / 02期
关键词：
endovascular; intraarterial; glioblastoma; virotherapy; oncolytic; stem cell; HEPATIC ARTERIAL INFUSION; MESENCHYMAL STEM-CELLS; ONCOLYTIC ADENOVIRUS; RECURRENT GLIOBLASTOMA; HERPES-VIRUS; PHASE-I; THERAPY; CANCER; GLIOMA; MUTANT;
D O I：
10.3171/2020.11.FOCUS20845
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Oncolytic viruses (OVs) have been used in the treatment of cancer, in a focused manner, since the 1990s. These OVs have become popular in the treatment of several cancers but are only now gaining interest in the treatment of glioblastome (GBM) in recent clinical trials. In this review, the authors discuss the unique applications of intraarterial (IA) delivery of OVs, starting with concepts of OV, how they apply to IA delivery, and concluding with discussion of the current ongoing trials. Several OVs have been used in the treatment of GBM, including specifically several modified adenoviruses. IA delivery of OVs has been performed in the hepatic circulation and is now being studied in the cerebral circulation to help enhance delivery and specificity. There are some interesting synergies with immunotherapy and IA delivery of OVs. Some of the shortcomings are discussed, specifically the systemic response to OVs and feasibility of treatment. Future studies can be performed in the preclinical setting to identify the ideal candidates for translation into clinical trials, as well as the nuances of this novel delivery method.
引用
收藏
页码：1 / 9
页数：9
相关论文
共 60 条
[31]   Selective intra-arterial infusion of rAd-p53 with chemotherapy for advanced oral cancer: a randomized clinical trial [J].
Li, Yi ;
Li, Long-Jiang ;
Wang, Li-Juan ;
Zhang, Zhuang ;
Gao, Ning ;
Liang, Chen-Yuan ;
Huang, Yuan-Ding ;
Han, Bo .
BMC MEDICINE, 2014, 12
[32]   Intracarotid delivery of oncolytic HSV vector G47Δ to metastatic breast cancer in the brain [J].
Liu, R ;
Martuza, RL ;
Rabkin, SD .
GENE THERAPY, 2005, 12 (08) :647-654
[33]   Cancer Stem Cells and Immunosuppressive Microenvironment in Glioma [J].
Ma, Qianquan ;
Long, Wenyong ;
Xing, Changsheng ;
Chu, Junjun ;
Luo, Mei ;
Wang, Helen Y. ;
Liu, Qing ;
Wang, Rong-Fu .
FRONTIERS IN IMMUNOLOGY, 2018, 9
[34]  
Mansouri A, 2017, GLIOBLASTOMA, P27, DOI 10.15586/codon.glioblastoma.2017.ch2
[35]   EXPERIMENTAL-THERAPY OF HUMAN GLIOMA BY MEANS OF A GENETICALLY ENGINEERED VIRUS MUTANT [J].
MARTUZA, RL ;
MALICK, A ;
MARKERT, JM ;
RUFFNER, KL ;
COEN, DM .
SCIENCE, 1991, 252 (5007) :854-856
[36]   Current State of Immunotherapy for Treatment of Glioblastoma [J].
McGranahan, Tresa ;
Therkelsen, Kate Elizabeth ;
Ahmad, Sarah ;
Nagpal, Seema .
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2019, 20 (03)
[37]   Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas [J].
Nakamizo, A ;
Marini, F ;
Amano, T ;
Khan, A ;
Studeny, M ;
Gumin, J ;
Chen, J ;
Hentschel, S ;
Vecil, G ;
Dembinski, J ;
Andreeff, M ;
Lang, FF .
CANCER RESEARCH, 2005, 65 (08) :3307-3318
[38]   Therapeutic potential and challenges of natural killer cells in treatment of solid tumors [J].
Navarro, Andrea Gras ;
Bjorklund, Andreas T. ;
Chekenya, Martha .
FRONTIERS IN IMMUNOLOGY, 2015, 6
[39]  
Pasciak AS, 2020, EJNMMI RES, V10, DOI 10.1186/s13550-020-00679-1
[40]   Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma [J].
Patel, Anoop P. ;
Tirosh, Itay ;
Trombetta, John J. ;
Shalek, Alex K. ;
Gillespie, Shawn M. ;
Wakimoto, Hiroaki ;
Cahill, Daniel P. ;
Nahed, Brian V. ;
Curry, William T. ;
Martuza, Robert L. ;
Louis, David N. ;
Rozenblatt-Rosen, Orit ;
Suva, Mario L. ;
Regev, Aviv ;
Bernstein, Bradley E. .
SCIENCE, 2014, 344 (6190) :1396-1401
123456